M&A / Deals Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout pharminent March 31, 2026
M&A / Deals Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy pharminent March 31, 2026
Clinical Data PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease pharminent March 31, 2026
M&A / Deals Biogen, with $5.6B Apellis buy, builds out immunology offerings pharminent March 31, 2026
Other S16 Ep42: Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD pharminent March 31, 2026
Other Biotech IPOs stayed at slow pace, but grew larger in the first quarter of 2026 pharminent March 31, 2026
Other Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team Photo pharminent March 31, 2026
Regulatory S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD pharminent March 30, 2026
Clinical Data Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout pharminent March 30, 2026
Regulatory Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug pharminent March 30, 2026
Clinical Data Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline pharminent March 30, 2026
Market Access The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments pharminent March 30, 2026
Other S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC pharminent March 27, 2026
Regulatory Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents pharminent March 27, 2026
M&A / Deals Novartis targets Xolair successor in buyout of startup Excellergy pharminent March 27, 2026
M&A / Deals Merck’s deal for Terns sparks debate over a possible biotech bidding war pharminent March 26, 2026
Regulatory FDA clears Denali drug in ‘clear step’ for rare disease biotechs pharminent March 26, 2026
Clinical Data Wave crashes on obesity drug update; Kodiak’s reboot pays dividends pharminent March 26, 2026
M&A / Deals Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug pharminent March 25, 2026
M&A / Deals Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases pharminent March 24, 2026